Kenneth Allen Myszkowski Sells 27,167 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski sold 27,167 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $19.83, for a total value of $538,721.61. Following the transaction, the chief financial officer now owns 473,433 shares of the company’s stock, valued at approximately $9,388,176.39. This represents a 5.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Arrowhead Pharmaceuticals Price Performance

NASDAQ ARWR opened at $19.75 on Friday. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $17.05 and a 1 year high of $39.83. The business’s fifty day moving average is $21.05 and its two-hundred day moving average is $22.53. The stock has a market capitalization of $2.46 billion, a P/E ratio of -3.93 and a beta of 0.97. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ARWR. Commonwealth Equity Services LLC raised its holdings in Arrowhead Pharmaceuticals by 3.7% during the 2nd quarter. Commonwealth Equity Services LLC now owns 34,663 shares of the biotechnology company’s stock worth $901,000 after buying an additional 1,250 shares during the period. Rhumbline Advisers raised its holdings in shares of Arrowhead Pharmaceuticals by 2.9% during the second quarter. Rhumbline Advisers now owns 383,029 shares of the biotechnology company’s stock valued at $9,955,000 after acquiring an additional 10,924 shares during the period. TD Asset Management Inc lifted its position in shares of Arrowhead Pharmaceuticals by 90.8% in the 2nd quarter. TD Asset Management Inc now owns 54,200 shares of the biotechnology company’s stock valued at $1,409,000 after acquiring an additional 25,800 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Arrowhead Pharmaceuticals by 67.3% in the 2nd quarter. Victory Capital Management Inc. now owns 41,090 shares of the biotechnology company’s stock worth $1,068,000 after purchasing an additional 16,534 shares during the period. Finally, Arizona State Retirement System grew its position in Arrowhead Pharmaceuticals by 2.4% during the 2nd quarter. Arizona State Retirement System now owns 34,685 shares of the biotechnology company’s stock worth $901,000 after purchasing an additional 821 shares in the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Sanford C. Bernstein reduced their price target on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research report on Friday, November 29th. Citigroup decreased their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Friday, December 20th. Chardan Capital reiterated a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, December 12th. Finally, StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $43.33.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.